Aegis Capital Lifts PT on Navidea Biopharma (NAVB) to $2.50; Lymphoseek Sales Encouraging

March 6, 2014 3:18 PM

Aegis Capital is raising its price target on Navidea Biopharmaceuticals, Inc (AMEX: NAVB) by 25 percent from $2 to $2.50 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found